Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation.
Hisham A BadreldinJahad AlghamdiOmar AlshayaAbdulmajeed AlshehriLamya AlreshoudRenad AltoukhiSenthilvel VasudevanWesam W IsmailMohamed Salih Aziz MohamedPublished in: International journal of general medicine (2020)
Pharmacodynamics and pharmacokinetics interactions are common in more than half of the patients with NVAF receiving apixaban for stroke prevention in this real-world analysis. Some of these interacting medications are not indicated. Drug-drug interactions should always be considered and monitored with apixaban with a regular assessment of the need for any interacting medication.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- heart failure
- protein kinase
- percutaneous coronary intervention
- adverse drug
- healthcare
- venous thromboembolism
- emergency department
- drug induced
- risk assessment
- coronary artery disease
- mitral valve